Cullinan Oncology is a biotechnology business based in the US. Cullinan Oncology shares (CGEM) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $12.58 – a decrease of 17.78% over the previous week. Cullinan Oncology employs 85 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $12.58 |
|---|---|
| 52-week range | $7.64 - $30.19 |
| 50-day moving average | $16.67 |
| 200-day moving average | $18.54 |
| Wall St. target price | $32.44 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-2.84 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $13.1 from 2024-11-19
| 1 week (2024-11-14) | -14.38% |
|---|---|
| 1 month (2024-10-21) | -19.14% |
| 3 months (2024-08-21) | -27.30% |
| 6 months (2024-05-21) | -43.44% |
| 1 year (2023-11-21) | 51.45% |
|---|---|
| 2 years (2022-11-21) | 2.66% |
| 3 years (2021-11-19) | 19.47 |
| 5 years (2019-11-18) | N/A |
| Gross profit TTM | $18.9 million |
|---|---|
| Return on assets TTM | -20.4% |
| Return on equity TTM | -26.53% |
| Profit margin | 0% |
| Book value | $10.80 |
| Market Capitalization | $890.9 million |
TTM: trailing 12 months
We're not expecting Cullinan Oncology to pay a dividend over the next 12 months.
You may also wish to consider:
Cullinan Oncology's shares were split on a 2:1 basis on 30 August 2009 . So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Cullinan Oncology shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Cullinan Oncology shares which in turn could have impacted Cullinan Oncology's share price.
Over the last 12 months, Cullinan Oncology's shares have ranged in value from as little as $7.64 up to $30.1886. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cullinan Oncology's is -0.117. This would suggest that Cullinan Oncology's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Cullinan Oncology has bucked the trend.
To put Cullinan Oncology's beta into context you can compare it against those of similar companies.
Cullinan Therapeutics, Inc. , a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.